What Is Nicotine Withdrawal Syndrome?

Nicotine withdrawal syndrome is the set of physical and psychological symptoms that arise when a smoker stops or significantly reduces tobacco use. It is a direct manifestation of the neurochemical dependence that nicotine produces in the brain — and it represents the main barrier to smoking cessation.

Smoking is recognized by the WHO as a chronic disease of dependence, classified in ICD-11 as Tobacco Use Disorder. Nicotine is one of the most addictive substances known — with high dependence potential, comparable to or greater than that of other psychoactive substances on some epidemiological measures. About 70% of smokers want to quit, but only 3-5% succeed without help.

Understanding withdrawal as a neurobiological phenomenon — not as a "lack of willpower" — is essential so smokers seek and receive the right treatment. Effective treatments exist that raise the chances of successful cessation. With varenicline, for example, they more than double compared with placebo.

1

Neurochemical Dependence

Nicotine permanently rewires dopaminergic reward circuits, creating physical and psychological dependence that explains why quitting is só hard.

2

Temporary Symptoms

Physical withdrawal peaks at 2-3 days and improves significantly within 2-4 weeks. Symptoms are temporary but intense.

3

Effective Treatment

Nicotine replacement therapy, varenicline, and bupropion raise the chances of cessation. Adequate support makes all the difference.

1.3 bn
smokers worldwide
70%
want to quit smoking
3-5%
manage to quit without help
2.3x
the chance of quitting with varenicline, compared with placebo (Cochrane 2023)

Pathophysiology

Nicotine reaches the brain within 7-10 seconds after inhalation, binding to nicotinic acetylcholine receptors (nAChR) in the mesolimbic reward system. This triggers dopamine release in the nucleus accumbens — the same circuit activated by other drugs of abuse — producing pleasure and stress relief.

Pathophysiology of nicotine dependence: binding to nAChR receptors, dopamine release in the nucleus accumbens, upregulation of nicotinic receptors, and the withdrawal-reinforcement cycle
Pathophysiology of nicotine dependence: binding to nAChR receptors, dopamine release in the nucleus accumbens, upregulation of nicotinic receptors, and the withdrawal-reinforcement cycle

Neuroadaptation and Tolerance

With chronic exposure, the brain undergoes neuroadaptation: there is an increase in the number of nicotinic receptors (upregulation) to compensate for continuous desensitization. When the smoker stops smoking, these supernumerary receptors remain unoccupied, generating a state of dopaminergic hypoactivity that manifests as discomfort, irritability, and craving.

Multiple Neurotransmitters

Beyond dopamine, nicotine modulates the release of norepinephrine (alertness and concentration), serotonin (mood), GABA (relaxation), glutamate (memory), and endorphins (analgesia). Withdrawal affects all of these systems simultaneously, explaining the diversity of symptoms.

Symptoms

Withdrawal symptoms begin 2-12 hours after the last cigarette, peak at 24-72 hours, and gradually improve over 2-4 weeks. Some symptoms, such as craving and increased appetite, can persist for months. Intensity varies with the degree of dependence.

Symptoms of Nicotine Withdrawal

  • Intense craving for tobacco

    Urgent, overwhelming urge to smoke. Each episode typically lasts 3-5 minutes but can be very intense — the leading cause of relapse.

  • Irritability, frustration, or anger

    One of the most common and disruptive symptoms. It can significantly strain relationships and the workplace during the first weeks.

  • Anxiety

    Paradoxically, anxiety worsens in the first weeks of cessation before improving. Nicotine was used as an "anxiolytic," and its withdrawal unmasks underlying anxiety.

  • Difficulty concentrating

    Transient attentional déficit driven by reduced norepinephrine. It can impair work performance during the first 2-3 weeks.

  • Depressed mood

    Lower dopamine causes transient anhedonia. In people with a history of depression, it can trigger a depressive episode.

  • Insomnia or sleep disturbances

    Difficulty falling asleep, fragmented sleep, vivid dreams (especially with nicotine replacement). Improves in 1-2 weeks.

  • Increased appetite and weight gain

    Average gain of 4-5 kg in the first months. Driven by increased appetite, a slower metabolism, and replacing the oral habit.

  • Restlessness

    An inability to stay still, with motor agitation. Linked to dopaminergic hypoactivity.

  • Constipation

    Nicotine stimulates intestinal peristalsis. Withdrawal can cause transient constipation for 1-2 weeks.

Diagnosis

Diagnosing nicotine dependence and the withdrawal syndrome is clinical. The Fagerstrom Test for Nicotine Dependence (FTND) is the most widely used instrument to assess the degree of dependence and guide treatment selection. Serum or urinary cotinine can objectively confirm tobacco use.

DSM-5 Criteria for Tobacco Withdrawal

Source: American Psychiatric Association — DSM-5

Criterion A: Daily tobacco use for at least several weeks
  1. Daily tobacco use for a prolonged period before abrupt cessation or reduction
Criterion B: 4 or more symptoms within 24h after cessation
At least 4 symptoms must be present
  1. Irritability, frustration, or anger
  2. Anxiety
  3. Difficulty concentrating
  4. Increased appetite
  5. Restlessness
  6. Depressed mood
  7. Insomnia
Additional criteria
  1. Symptoms cause clinically significant distress or functional impairment
  2. Symptoms are not attributable to another medical condition or mental disorder

Fagerstrom Test — Degrees of Dependence

ScoreDegree of DependenceClinical Implications
0-2LowMay attempt cessation without pharmacotherapy. Behavioral support may be sufficient.
3-4ModeratePharmacotherapy recommended. NRT at standard doses or bupropion.
5-6HighPharmacotherapy essential. Consider combination treatment. NRT at higher doses.
7-10Very highCombination therapy (NRT + bupropion or varenicline). Intensive follow-up.

Differential Diagnosis

Depression

Read more
  • Depressed mood persisting beyond the withdrawal period
  • Generalized anhedonia
  • Does not improve after weeks without smoking
Diagnostic testsPHQ-9Interview
  • Anxiety persisting beyond withdrawal
  • Multiple domains of worry
  • Does not resolve after adaptation to withdrawal
Diagnostic testsGAD-7

Hypothyroidism (cause of weight gain)

  • Disproportionate weight gain after cessation
  • Persistent fatigue
  • Abnormal TSH
Diagnostic testsTSH

Withdrawal Syndrome from Another Substance

  • Concurrent use of alcohol/anxiolytics
  • Symptoms more severe than expected for tobacco
Diagnostic testsSubstance screening

Occupational Stress/Burnout

Read more
  • Irritability and craving tied to the work context
  • Worsening in work situations
Diagnostic testsOccupational evaluationMBI

Depression and Anxiety in Smoking Cessation

Quitting smoking can precipitate or unmask underlying depression and anxiety. Nicotine acts as both an antidepressant and anxiolytic, raising dopamine, serotonin, and norepinephrine. When smoking stops, the loss of those neurobiological effects can trigger depressed mood, anhedonia, and heightened anxiety, especially in the first 2-4 weeks. The clinical question becomes: are these symptoms nicotine withdrawal, or an underlying psychiatric disorder?

Nicotine withdrawal peaks in the first 3-5 days and steadily improves over 2-4 weeks. If depressed mood, intense anhedonia, or anxiety persist past 4 weeks, investigate an underlying psychiatric disorder. PHQ-9 and GAD-7 are quick screening scales. Bupropion — a cessation pharmacotherapy — is also an antidepressant, só it can mask underlying depression while cessation treatment is active.

Weight Gain and Hypothyroidism

Weight gain after quitting is expected — about 4-5 kg in the first 6-12 months. Nicotine suppresses appetite, raises basal metabolism, and lowers metabolic efficiency; without it, metabolism slows and appetite climbs. The gain is predictable and clinically far smaller than the ongoing risks of smoking.

When weight gain is disproportionate (over 8-10 kg) or paired with persistent fatigue, cold intolerance, and other complaints, rule out hypothyroidism. A simple TSH guides the diagnosis. Smoking can mask hypothyroidism (nicotine interferes with thyroid metabolism), and the condition often becomes symptomatic after quitting. Treating hypothyroidism helps maintain abstinence by resolving the fatigue.

Context-Linked Craving and Polysubstance Use

Tobacco craving can be intense and is triggered by specific contexts: work stress, coffee or alcohol, post-meal moments, social situations. When craving and irritability are driven mainly by work, evaluate burnout or job stress as a precipitating factor — treating the stressor can reduce situational craving.

Polysubstance use complicates smoking cessation. Concurrent alcohol use, especially heavy drinking, is associated with lower chances of successful cessation — alcohol is a potent smoking trigger. Benzodiazepines may mask early withdrawal symptoms. Screen for other substances (AUDIT for alcohol, ASSIST) in patients with withdrawal symptoms more intense than expected, or after several failed attempts.

Treatment

Smoking cessation treatment combines behavioral intervention and pharmacotherapy. The three first-line pharmacotherapies — nicotine replacement therapy (NRT), varenicline, and bupropion — are effective and safe. The combination of counseling and medication is more effective than any approach in isolation.

Pharmacotherapy for Smoking Cessation

TreatmentMechanismEfficacyConsiderations
Varenicline (Champix)Partial nAChR agonist — reduces craving and dulls the pleasure of smokingAbout 22% at 12 months (vs 8-10% with placebo)Most effective as monotherapy. Nausea is the most common side effect.
NRT (patch + gum/lozenge)Nicotine replacement — reduces withdrawal without combustionNearly doubles the chance of quitting vs controlCombined forms (patch + rescue) outperform any single form.
BupropionInhibition of dopamine and norepinephrine reuptakeAbout 15% at 12 monthsEspecially useful with comorbid depression. Reduces weight gain.
Varenicline + NRTCombination of mechanismsLimited evidenceMay be considered in high dependence, under medical guidance.
Weeks 1-2 (pré-cessation)

Assess dependence (Fagerstrom). Set the quit date. Start varenicline or bupropion (both need 1-2 weeks of titration before quit day).

Quit Day and Week 1

Quit abruptly. Withdrawal peaks (days 2-3). Full pharmacological support. Manage craving with the 4 Ds: delay, drink water, do something, deep breathe.

Weeks 2-4

Physical symptoms gradually improve. Continue pharmacotherapy. Identify and manage behavioral triggers.

Months 1-3

Physical withdrawal resolved. Situational craving persists. Focus on relapse prevention and handling high-risk situations.

Months 3-6

Consolidate gains. Gradually taper NRT if applicable. Continue varenicline for 12-24 weeks depending on response.

Do

  • Set the quit date and start varenicline or bupropion 1-2 weeks before, during titration
  • Identify and manage behavioral triggers
  • Manage craving with the 4 Ds: delay, drink water, do something, deep breathe

Avoid

  • Overlook concurrent alcohol use: it is associated with lower chances of successful cessation and is a potent smoking trigger
  • See relapse as failure: it is part of recovery
  • Consider the e-cigarette a safe way to quit smoking
The essentials so far
  1. Smoking cessation treatment combines behavioral intervention and pharmacotherapy.
  2. The three first-line pharmacotherapies — nicotine replacement therapy (NRT), varenicline, and bupropion — are effective and safe.
  3. The combination of counseling and medication is more effective than any approach in isolation.
Continue: Acupuncture as Treatment

Acupuncture as Treatment

Acupuncture, especially auriculotherapy, is widely used as a complementary therapy for smoking cessation. Proposed mechanisms include endorphin release that reduces craving, modulation of the dopaminergic reward system, parasympathetic activation via the vagus nerve, and reduction of anxiety associated with withdrawal.

Stimulating specific auricular points may modulate vagus nerve activity and influence brain centers involved in dependence. Complementary body acupuncture may reduce stress and irritability — withdrawal symptoms that often precipitate relapse.

Acupuncture is used to complement conventional cessation therapies. It may be considered, as a complement, by patients who want an integrative approach, knowing that evidence of benefit for cessation is inconclusive; contraindications to pharmacotherapy should be assessed by the physician.

Prognosis

With appropriate treatment, 12-month abstinence rates in trials are around 15-25%, well above the 3-5% of people who try to quit unaided. Most successful ex-smokers tried to quit more than once before succeeding definitively. Each attempt increases the chance of future success.

Health benefits begin quickly: blood pressure normalizes within 20 minutes, smell and taste improve in 48 hours, and lung function improves significantly within 3 months. At 1 year, cardiovascular risk drops by half. At about 10 years, lung cancer risk falls to roughly half that of people who keep smoking, and keeps declining afterwards.

Relapse is common and should be seen not as failure but as part of recovery. Relapse risk is highest in the first 3 months. The most frequent triggers are stressful situations, alcohol, and exposure to other smokers.

Myths and Facts

Myth vs. Fact

Myth

Quitting smoking is just a matter of willpower.

Fact

Nicotine dependence is a chronic disease with a neurobiological basis. Nicotine causes persistent neuroadaptations in reward circuits that make cessation extremely difficult without support. Pharmacological treatment raises the chances of success — needing help is not 'weakness'.

Myth vs. Fact

Myth

The e-cigarette is a safe way to quit smoking.

Fact

Although e-cigarettes contain fewer toxins than conventional cigarettes, they are not risk-free. Their long-term effects remain unknown, and most countries have not approved them as cessation treatment. Proven therapies — varenicline, NRT, and bupropion — are preferable.

Myth vs. Fact

Myth

Cutting down gradually is better than quitting all at once.

Fact

Evidence shows that quitting abruptly matches or beats gradual reduction. Abrupt cessation with pharmacological support is the most studied and most recommended method. For smokers who cannot stop abruptly, however, gradual reduction with NRT is a valid alternative.

When to Seek Help

If you want to quit smoking, the best time to seek help is now. Appropriate treatment makes all the difference. You do not have to go through this alone.

Frequently asked questions

Frequently Asked Questions about Smoking Cessation